Ferring Pharmaceuticals launches nocturia treatment Noqdirna in the UK

Ferring Pharmaceuticals has announced the UK launch of Noqdirna, a new symptomatic therapy for nocturia due to idiopathic nocturnal polyuria in adults, including the over 65s.

The drug has been approved by the UK Medicines and Healthcare Products Regulatory Agency and has been developed to reduce the amount of urine the kidneys produce. Tablets are administered sublingually in gender-specific low doses.

Nocturia, or the need to wake at night to pass urine, affects around 8.63 million people in the UK, with night-time overproduction of urine thought to be a contributing factor in 76 to 88 percent of these cases.

In a pair of phase III studies, Noqdirna was shown to significantly reduce the average number of night-time urinations in both men and women.

Steve Howson, Ferring UK's general manager, said: "This is a significant milestone in making sure patients of all ages, including those over 65 years old, have a treatment option to help reduce the burden of their condition."

Nocturia can result in an increase in falls and fractures, due to the need for night-time bathroom trips, or due to sleepiness during the day. It can also impact upon physical, mental and emotional health, leading to a decreased quality of life and an increased risk of morbidity and mortality.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.